News 
Market Data 
Discover
Replies to post #215561 on Anavex Life Sciences Corp (AVXL)
jfsmart
Comments307 | + Follow
Pump and Dump? Let's look at some of the Author's "hype". Last year, her urged his followers to "dump" ACAD as it had been taken to the "wood shed" and was way over priced. That was at $30/share and he disclosed he owned "Puts". Two months later, ACAD was close to $60. Great call! Or how about EYES, his "long" recommendation (and position) back in last May at around $9 or $10, convincing everyone it was going to $30. It's sitting at under $6 today, right? Another great miscalculation.
A couple other year ago "authoritative" predictions with positions from last March and May disclosures: Ya gotta love his "long" position and recommendations for CAPN at $6/shr with a knowledgable insight that it shoud be worth $10 to $20 shr by now, a year later. It's selling for $1.24. Or, how about hos long position and great recommendations for BIAD at 25 cents/sh. It's selling at around 3 cents, today.
I only read a half dozen or so of your posts available from Seeking Alpha. I had to stop, I was laughing so hard! What stood out, however, that in each of the articles I did view, you seemed totally focused on using this venue to slam or promote a stock in which you ALWAYS held. the other outstanding conclusion I drew, was that you were ALWAYS consistently WRONG in your projecctions and price predictions.
I guess there is something to be said for being consistent. It's very much like my experience in picking winners at the horse track. I'd spend hours reading tips and racing forms, but when it was all said and done, my wife asked me who I picked, and she bet against me- usually winning.
From reading your Bio, it appears you're still looking for a job. I don't think you'll get any offers based upon your stock-picking recommendation successes. I'd encourage you to rethink your messaging. Offer facts without a corresponding equity interest based on some original research, not other writer's promotional pieces already in publication. Offering self-serving, biased information is a waste of ink and offers little in the way of job appeal!
27 Apr 2016, 02:00 PM
10/22/19 12:02 AM
AVXL Miracle Drug With A Toxic Financing Set For A Severe Decline In Price by
Edward Vranic, CFA
Apr. 26, 2016 10:00 AM ETAnavex Life Sciences Corp. (AVXL)152 Comments
Summary
Anavex Life Sciences rose 16% on Monday due to feel-good news stories on the impact of its early-stage Alzheimer's drug.
AVXL has gotten into a vulture financing deal of up to $50 million with Lincoln Park Capital, a fund that has been synonymous with poor stock performance.
LPC has nine other deals in the past year similar in nature to AVXL. Eight of those companies have declined in share price, averaging a 38% loss.
If AVXL truly has compelling science, it should be able to attract real institutional investment. Institutions own less than 3% of the stock.
I expect AVXL to decline to $4 or less by the end of the year.
A compelling story came out of Australia for Anavex Life Sciences Corp. (NASDAQ:AVXL), which caused the stock to move up 16% on Monday. In addition to one Alzheimer's patient regaining the ability to paint, another was able to play the piano once again after being treated with ANAVEX™ 2-73. These feel-good stories resonate with investors like myself who like to invest in speculative biotech companies.
Unfortunately, these types of exciting speculative investments have burned me in the past. What I have learned about investing in these early stage biotech and healthcare companies is it's not so much about the science -
